<DOC>
	<DOCNO>NCT02255500</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics EXPAREL subject undergo femoral nerve block bupivacaine HCl unilateral total knee arthroplasty ( TKA ) .</brief_summary>
	<brief_title>EXPAREL Infiltration Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl Total Knee Arthroplasty</brief_title>
	<detailed_description>On Day 1 , eligible subject receive single 20 mL dose bupivacaine hydrochloride ( HCl ) 0.5 % epinephrine 1:200,000 within 2 hour prior surgical procedure ultrasound-guided femoral nerve block ( FNB ) . EXPAREL 266 mg expand 60 mL preservative-free sterile normal saline infiltrate surgical site prior wound closure . There local coadministration two drug . Blood sample bupivacaine pharmacokinetic ( PK ) analysis obtain subject baseline ( prior bupivacaine HCl administration nerve block ) , 15 minute , 30 minute , 1 , 2 , 4 , 8 , 12 , 24 , 48 , 72 , 96 hour begin EXPAREL administration , Day 14 .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Males females ≥18 year age . 2 . American Society Anesthesiologists ( ASA ) physical status 1 , 2 , 3 . 3 . Scheduled undergo femoral nerve block conjunction unilateral TKA . 4 . Female subject must surgically sterile , least 2 year postmenopausal , use medically acceptable method birth control . Females childbearing potential must document negative blood urine pregnancy test result within 24 hour surgery . 5 . Able provide inform consent , adhere study schedule , complete study assessment . 1 . History hypersensitivity idiosyncratic reaction amidetype local anesthetic opioids . 2 . Contraindication bupivacaine . 3 . Received bupivacaine local anesthetic within 7 day EXPAREL administration . 4 . Currently pregnant , nursing , plan become pregnant study within 1 month EXPAREL administration . 5 . Planned concurrent surgical procedure ( e.g. , bilateral TKA ) . 6 . Body weight &lt; 50 kg ( 110 pound ) body mass index ≥45 kg/m2 . 7 . Received investigational drug within 30 day prior EXPAREL administration , and/or plan administration another investigational product procedure subject 's participation study . 8 . Previous participation EXPAREL study . 9 . Malignancy last 2 year , exception nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . 10 . Current historical evidence clinically significant disease condition , especially cardiovascular neurological condition , opinion Investigator , may increase risk surgery complicate subject 's postsurgical course . 11 . Clinically significant medical psychiatric disease , opinion Investigator , would constitute contraindication participation study , cause inability comply study requirement . In addition , subject ineligible receive EXPAREL meet follow criterion surgery : 12 . Any clinically significant event condition uncover surgery ( e.g. , excessive bleeding , acute sepsis ) might render subject medically unstable complicate subject 's postsurgical course .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Total knee arthroplasty</keyword>
</DOC>